Background: Although periconceptional glycemic control directly impacts perinatal outcome for pregestational diabetic women, these women still frequently enter pregnancy with suboptimal control of glycemia.
T HE IMPORTANCE of periconceptual intensive glycemic control for the prevention of congenital anomalies and spontaneous abortions in women with diabetes has been clearly established. [1] [2] [3] [4] [5] Earlier studies demonstrated a direct correlation between glycemic control and hemoglobin A 1c values and the incidence of congenital anomalies and spontaneous abortions. 6 , 7 Later studies demonstrated that with intensification of glycemic control prior to conception and during the early weeks of pregnancy, the incidence of congenital anomalies and spontaneous abortions could be significantly reduced. 8, 9 Understanding the importance of periconceptual intensive glycemic control led to the strategy of preconception care of women with diabetes. The goals of preconception care include education, assessment of risks associated with pregnancy, modification (if needed) of diet, insulin therapy, frequency of self-monitoring of glucose levels, and improvement in glycemic control. Despite the universal acceptance in the obstetric community of the efficacy of preconception care, it was our observation that many patients with diabetes did not seek or were not referred for preconception care and maintained suboptimal glycemic control at the time of their first prenatal visit.
In 1993, results of the multicenter Diabetes Control and Complications Trial 10 were published and provided important and convincing evidence that in contrast to conventional glycemic control, intensive glycemic control in patients with diabetes delays the onset For editorial comment see page 1299
and slows the progression of diabetic retinopathy, nephropathy, and neuropathy. By delaying the onset of endorgan damage and disability, intensive therapy is estimated to be cost-effective. 11 The intensive therapy regimen was designed to achieve blood glucose levels as close to the reference range as possible.
It was our expectation that after dissemination of the resultsoftheDiabetesControlandComplicationsTrial,more women of childbearing age would enter pregnancy with better glycemic control. The purpose of the present study was to determine what percentage of women with diabetes enter pregnancy with optimal glycemic control. We also sought to determine what factors were associated with achieving optimal periconceptional glycemic control.
RESULTS
Between October 1994 and March 1997, 94 pregestational diabetic women presented for prenatal care, and 55 participated in the study. The 39 women not included either declined to participate or were not brought to the investigators' attention. The mean hemoglobin A 1c level and gestational age at first visit of both the entire pregnant diabetic population and the study cohort were not significantly different (PϾ.05). The proportion of patients with optimal, adequate, and suboptimal glycemic control was similar between the study patients and the entire population of pregestational diabetic women ( Table 1) .
Of the patients who participated in the study, 33 (60%) had suboptimal control while only 6 (11%) had hemoglobin A 1c values in the normal range. Women with suboptimal glycemic control did not differ from women with good or adequate control with regard to payer status, maternal age, race, or maternal weight (PϾ.05). Multiparity, obesity (ideal body weight Ն120%), presence of vascular complications, and age at diagnosis of diabetes were not factors predictive of suboptimal glycemic control ( Table 2) . However, women with a prior poor outcome of pregnancy were significantly more likely to enter pregnancy with poor glycemic control (P = .02).
Unconditional logistic regression analysis revealed that not being advised to achieve target glucose or hemoglobin A 1c values was significantly associated with entering pregnancy with poor glycemic control (P = .02) ( Table 3) . A total of 47 patients (86%) were followed Microsoft Excel (Microsoft, Seattle, Wash) and SPSS for Windows (SPSS Inc, Chicago, Ill) were used for all analyses. The data were analyzed using unconditional logistic regression to obtain point estimates of risk between the factors, such as prior poor outcome of pregnancy, gravidity, percentage of ideal body weight, age at diagnosis of diabetes, vascular complications, and the outcome variable of glycemic control. Unconditional logistic regression analysis was also used to evaluate the relationship between responses to the questionnaire and glycemic control. The logistic model provides odds ratios that are upwardly biased estimates of risk ratios when the outcome of interest (suboptimal glycemic control) is present in 60% of the cohort evaluated. The odds ratio is used as a measure of association independent of its estimate of a risk ratio. 12 2 tests were used to compare proportions and Student t tests were used to compare means, as appropriate. A P value of less than .05 was considered significant.
PATIENTS AND METHODS
Based on recent recommendations by the American Diabetes Association, we defined suboptimal glycemic control as a hemoglobin A 1c value greater than 0.08. 13 The normal nondiabetic hemoglobin A 1c range at our institution is 0.04 to 0.06, and we defined optimal control as a periconceptional value in this range. Adequate control was defined as a hemoglobin A 1c level between 0.06 and 0.08. Hemoglobin A 1c measurements were done at our institution using cation exchange chromatography (DiaSTAT Hemoglobin A 1C program, Bio-Rad Laboratories, Hercules, Calif).
up before conception by a family practitioner, internist, or endocrinologist for their diabetes, 45 (82%) monitored their blood glucose level at least 3 times per day, 33 (60%) stated that they had been advised to avoid an unplanned pregnancy, and 34 (62%) stated that they were aware of the complications of diabetes in pregnancy, but these were not significant factors associated with periconceptional glycemic control. Overall, 29 diabetic women (53%) stated that they had planned their pregnancies, but only 12 (22%) saw a physician before conception to modify their insulin intake or glycemic control.
COMMENT
Pregestational diabetes complicates 1 in 200 pregnancies.
14 Congenital anomalies represent the leading cause of perinatal mortality in infants of diabetic mothers and occur early in pregnancy, by 5 to 8 weeks of gestation, usually before patients present for prenatal care. 3 The likelihood of a congenital anomaly is directly related to the degree of glycemic control at the time of conception and during organogenesis. Data from the Joslin Clinic indicate that hemoglobin A 1c values greater than 6 SDs above the mean (Ͼ0.09) increase the risk for the development of malformations. 6 To improve periconceptional glycemic control and prevent malformations, diabetic women must be encouraged to seek preconception care; this strategy has been found to be effective in clinical trials. However, the findings of our study and a recent study by Rodgers and Rodgers 15 support our impression that preconception care and optimization of periconceptual glycemic control is not occurring in clinical practice. Only 12% of patients in our cohort had normal hemoglobin A 1c concentrations at their first prenatal visit, and almost 40% of patients had hemoglobin A 1c values in the range associated with an increased risk of congenital malformations.
Why is the strategy of preconception care ineffective in clinical practice? We sought to determine what factors might influence whether patients with diabetes enter pregnancy with adequate or suboptimal glycemic control. We found that women who were not advised to achieve target hemoglobin A 1c and glucose levels in preparation for pregnancy were significantly more likely to enter pregnancy with suboptimal glycemic control. It is our impression that patient education delivered by physicians may be insufficient to prepare patients for possible diabetic complications during pregnancy. Although most patients were followed up by a physician for their diabetes and most were counseled to plan their pregnancies, patients may not be properly educated about the specific target levels of blood glucose and hemoglobin A 1c they should achieve. Achieving target blood glucose levels may require more frequent communication and testing prior to conception. We suspect that this does not happen with many patients. Interestingly, patients with a prior adverse outcome of pregnancy were more likely to have suboptimal control of their blood glucose levels. Our interpretation of this finding, based on clinical experience, is that there is a subgroup of patients with diabetes who do not adhere to recommendations regarding their care (diet, self-monitoring, and/or insulin doses). This may be due to attitude (ie, motivation) or organizational (ie, access to care) barriers. 16 Presently, it is not clear which strategies may be effective in eliminating these barriers.
We recognize the limitations of a questionnaire study and the subjective interpretation of our findings. However, it is clear from the initial hemoglobin A 1c values in the entire cohort of women with diabetes that optimal periconceptual control is not being achieved. We encourage other groups and investigators to determine how effectively periconceptional glycemic control is being achieved in populations of diabetic women of childbear- ing age. Since the completion of this study, the American Diabetes Association has published a new position statement on the standards of care for patients with diabetes. 17 This latest position recommends a hemoglobin A 1c goal of less than 0.07 for diabetic patients and specifically calls for preconception and contraceptive counseling in diabetic women of childbearing age. 17 Innovative techniques to improve physician and patient education and patient motivation and compliance are also needed.
Another major obstacle to the success of any preconception strategy is that many patients do not plan their pregnancies. Rodgers and Rodgers 15 found that 73% of diabetic women did not plan their pregnancies and speculated that this was possibly etiologic in suboptimal periconceptual glycemic control. Although in our study glycemic control was not significantly different between patients who stated that they planned or did not plan their pregnancies, we also observed 26 unplanned pregnancies (47%). We propose that in addition to preconceptional counseling, an ideal strategy for optimizing periconceptual glycemic control would be to implement strict monitoring of blood glucose levels for all diabetic women of childbearing age. The goal of intensive therapy, normalization of blood glucose levels, is the same as the goal of periconceptional glycemic control. Because the goals of these 2 strategies are similar, women who do not plan their pregnancies or who do not seek preconception care are still likely to enter pregnancy with optimal glycemic control. Patients who frequently monitor and adjust their diabetes regimen are more likely to maintain strict control of their blood glucose levels throughout pregnancy. It is our opinion that implementation of strict monitoring of blood glucose levels, in addition to its efficacy in reducing long-term complications in persons with diabetes, is likely to have a positive impact on preconception control and pregnancy outcome in diabetic women of childbearing age.
In conclusion, we have shown that diabetic women frequently enter pregnancy with poor glycemic control. Although many diabetic women are aware of the complications of diabetes in pregnancy, these patients may not be sufficiently educated about the target glucose levels recommended for periconceptual control. We propose that the implementation of an intensive effort to control blood glucose levels in all diabetic women of childbearing age, based on the findings of the Diabetes Control and Complications Trial, would obviate the need for preconception regimen changes and would result in patients entering pregnancy with better glycemic control.
